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Chapter 2 
Addressing Addiction and High Risk Behaviors Using the 
Integrated Public Health and Public Safety Approach 
Wilson M. Compton and Redonna K. Chandler 
The number of persons under justice supervision in the United States has increased markedly over 
the past 30 years, driven especially by an increase in use of justice sanctions to address crimes 
related to drug abuse and addiction. Such a shift has led the justice system to serve as a de facto 
partial quarantine system. While this situation may reflect broad trends to criminalize addiction-
related behavior and may also reflect deterioration of our health care system and its inability to deal 
with the most vulnerable in our standard facilities, it also provides an opportunity for public health 
strategies that reach populations which are otherwise hidden. One problem is that approaches to 
drug use issues that are purely justice-based are fraught with recidivism, and purely medical 
approaches to drug use issues are fraught with poor uptake—many persons who could benefit from 
treatment fail to participate. An alternative hybrid approach is the combined public health and 
public safety model, which may offer the most promise to address addiction, mental illness, and 
related health conditions within the criminal justice system. This model incorporates the strengths 
of health and justice systems to address the needs and weaknesses of each. Dual benefits can also 
encourage participation by both systems. In addition to offering promise in addressing substance 
use and other mental illnesses, a combined public health and public safety approach may allow 
rational approaches to targeting HIV/AIDS, tuberculosis, and other infectious diseases in a high-risk 
population. 
The absolute number and the proportion of the U.S. population involved in justice settings 
increased tremendously during the past 30 years. Between 1980 and 2008, the number of adults 
incarcerated in prison or jail increased nearly five-fold from approximately 500,000 to over 2.3 
million.1 Overall, in 2008 the number of adults in prison, jail, or some other form of correctional 
supervision (probation, parole, work release, etc.) exceeded 7.3 million.2 This represents 
approximately 3.2% of the adult (age 18+) population.3 As seen in Figure 2.1, the increases in 
incarceration were most dramatic during the late 1980s and early 1990s, with some leveling off in 
the past few years.2 It is well known that the increases in incarceration are largely related to 
increases in drug-related crimes.4 As a result, persons incarcerated exhibit very high rates of illicit 
drug abuse and addiction. Recent work has shown that approximately half of all those incarcerated 
meet the criteria for a DSM-IV (Diagnostic and Statistical Manual of Mental Disorders-IV) abuse or 
dependence on an illicit drug.5, 6 
<Insert Compton Figure 2.1 here> 
One impact of high rates of incarceration is that estimates of population rates of drug use 
disorders are distorted if one relies solely on the major general-population surveys.7 When data 
from drug use disorders collected from inmates8–11 were combined with results from a large 
noninstitutionalized sample of adults (the 2001–2002 National Epidemiologic Survey on Alcohol 
and Related Conditions, NESARC12), the summed overall projected estimates of the number of 
persons ages 18 and older with a DSM-IV illicit drug use disorder in the U.S. were 25.1% higher 
than the estimates from the noninstitutionalized sample alone (increased by 1,043,000 from 
4,159,000 to 5,202,000 persons). Estimates of the overall combined projected prevalence of a DSM-
IV illicit drug abuse disorder increased over the base by 12.0% and DSM-IV dependence by 53.8%. 
Thus, high rates of DSM-IV substance use disorders among inmates combined with a large inmate 
population results in an incomplete picture regarding drug use disorders in major U.S. national 
general population surveys, such as the National Survey on Drug Use and Health,13 because 
incarcerated persons are not included in the sampling frame. 
Given the proportion of drug addicts that are incarcerated, it appears that prisons and jails form a 
pseudo-quarantine system for these disorders and associated health conditions including serious 
mental illness, HIV, and hepatitis C. The question is whether this system is effective in terms of 
improving public health and public safety or if an alternative approach could be more beneficial. 
Racial Overrepresentation 
Certain racial and ethnic minorities are over-represented in the U.S. criminal justice system. In 
2002, approximately 43.8% of admissions to prison were African American.14 In addition, as shown 
in Figure 2.2, the number of persons incarcerated since the 1980s has been disproportionately 
African American.15 
<Insert Compton Figure 2.2 here> 
Co-Occurring Mental and Physical Disorders 
Psychiatric and substance use disorders frequently co-occur in the general population.12,16–18 
Psychiatric disorders are even more pronounced among those in the criminal justice system. 
According to the Bureau of Justice Statistics, 56% of all state prisoners, 45% of federal prisoners, 
and 64% of jail inmates have a mental health problem.19 These mental health problems span the full 
range of nonpsychotic and psychotic symptoms: 30% of jail inmates, 24% of state prisoners, and 
16% of federal prisoners reported major depression and 24% of jail inmates, 15% of state prisoners, 
and 10% of federal prisoners reported recent hallucinations or delusions.19 In addition, the majority 
of offenders with drug problems met criteria for a comorbid psychiatric disorder.20–22 Seventy-six 
percent of local jail inmates as well as 74% of state prisoners and 64% of federal prisoners with a 
mental health problem were found to also have substance abuse or dependence.19 High rates of 
mental illness among those incarcerated may relate to several factors including the increased use of 
jail and prison time for nonviolent drug offenses, lack of access to drug abuse treatment, and 
deterioration in the mental health treatment system. 
Infectious diseases such as tuberculosis, HIV, and hepatitis B and C are associated with illicit 
drug use and occur at higher rates in offender populations than in the general population.6 Recent 
research indicates that one in seven Americans living with HIV is released from a correctional 
facility.23 For certain minority groups this number is even higher, with an estimated one in five 
African American and Hispanics living with HIV in this country being released from a prison or 
jail.23 Availability of screening, treatment, and continuing care for these conditions appears to fall 
short of need,24–26 despite the fact that it is feasible to implement programs in correctional settings 
for HIV,27 28 hepatitis C,29,30 and tuberculosis.31 Programs to address these medical conditions are 
most available in prisons and some jails but less so in other parts of the justice system (probation, 
parole, etc.). This is in part due to the fact that incarcerated inmates have a constitutional right to 
health care.32 Continuity of treatment for released offenders with infectious disease is difficult, but 
important, not just for the individual’s health,33,34 but also for the health of the community.24,35–37 A 
stark example of treatment disruption for HIV was recently shown in a study of inmates who had 
been on anti-retroviral medications while incarcerated and then were followed after release.37 In this 
study, only 5% received prescriptions for antiretroviral treatment (ART) within two weeks after 
release.37 These issues have garnered the attention of public health practitioners and researchers 
interested in learning how to effectively address the significant treatment needs of this population. 
Addressing drug addiction and related health conditions, including mental illness and infectious 
diseases, for individuals involved in the criminal justice system is complicated. Historically, the 
public health and public safety systems have used different competing models to address these 
vexing issues. Recent efforts have attempted to develop a new blended model combing strengths 
from both public health and public safety systems. 
Public Health Approaches 
The public health approach to drug addiction and related health conditions is built on the concept 
that addiction is a disease requiring treatment which is offered on a voluntary basis to patients. 
Advances in clinical neuroscience support the neurobiological basis of addiction as a disease that 
affects the brain and behavior38 rather than a moral weakness.39 Key findings from neuroscience 
research demonstrate that repeated drug use leads to longstanding changes in brain functioning.40 
These findings provide a way to understand why drug addicts have such difficulty quitting drug use 
despite the most severe consequences. It also presents an explanation for relapse and why 
punishment alone is an ineffective strategy for reducing drug use, supporting the conceptualization 
of addiction as a chronic condition requiring sustained treatment.41,42 In addition, participation in 
drug abuse treatment provides an opportunity to screen for and treat related medical conditions 
including HIV and hepatitis C. 
Research documents that treatment can be effective in reducing drug use and infectious disease 
risk behaviors as well as in improving other important outcomes.43–45 Behavioral interventions have 
a strong evidence base, including cognitive therapies that teach coping skills and decision-making, 
contingency management interventions that shape and reinforce behaviors associated with 
abstinence, and motivational therapies that enhance the motivation to participate in treatment and in 
non-drug-related activities.43,46 Exciting new research is exploring the use of computer technology 
to deliver behavioral therapies and one study has found that some components of cognitive 
behavioral therapy can be delivered through an automated computer platform.47 The residential 
treatment approach that incorporates social learning theory in the construct of a therapeutic 
community has also been shown to be effective.48 In addition, medications such as methadone, 
buprenorphine, and naltrexone are effective for opiate addiction, and naltrexone, acamprosate, and 
topiramate can be effective for alcohol addiction.49,50 Finally, self-help support such as the 12-step 
Alcoholics Anonymous (and related) can be useful in supporting long-term behavior change.51 
Cost-effectiveness studies document the potential value of public health approaches to treating 
drug-involved offenders.52 In the United States, incarceration is estimated to cost about $22,000 per 
person per year53 and has minimal impact on long-term drug abuse beyond the incarceration phase. 
One specific treatment for opiate addiction, methadone, costs about $4,000 per person per year54,55 
and has demonstrated effectiveness in reducing both drug use and criminal activity,56 suggesting 
potential cost savings from this treatment approach. Overall, for every $1 spent, prison-based 
treatment saves between $2 and $6.57 These economic benefits of treatment reflect in part the 
reduction in criminal behavior.58,59 
A key weakness of the public health approach to drug addiction is the assumption that patients 
will recognize and accept their need for treatment. Large-scale epidemiological studies do not bear 
out this fact and in fact indicate that only 6% of those meeting the criteria of drug abuse and 31% of 
those meeting criteria for drug dependence actually access treatment in a given year.12 Many 
individuals who enter treatment drop out prior to completion or fail to receive ongoing recovery 
support services. In addition, many organizations and systems serving high-risk groups (e.g., 
medical care settings and criminal justice system) fail to implement effective interventions for 
addiction. For example, it is estimated that the vast majority of prisoners (80–85%) don’t participate 
in treatment despite clear need.5,60 
Public Safety Approaches 
The public safety approach to reducing the consequences of drug use and addiction, including 
illegal drug possession and sales and other drug-related crimes, is built on the concept that such 
drug use is primarily an issue of illegal behaviors, and so, punishment is the primary approach to 
changing behavior. As seen in the increases in arrests and judicial punishments (primarily 
probation, parole, and incarceration), this public safety approach has been a major policy and 
practice to address drug addiction in the United States.15 Unfortunately, in isolation, the public 
safety approach to addressing drug use behaviors has significant shortcomings as seen in the high 
rates of recidivism.61 Further, a strictly public health approach to addiction also does little to impact 
the spread and contraction of related medical conditions including HIV. 
A key assumption of the public safety approach is that incarceration will deter drug use. Yet, 
even in the constrained environment of incarceration, some individuals still have access to illicit 
drugs.62 Further, long periods of abstinence while incarcerated fail to protect an offender from 
relapse when released, and rates of relapse are quite high in drug addicts released from prison or 
jail. This period of time after release is also fraught with excess morbidity and mortality, with drug 
overdose as a major contributing factor.63 It has been suggested that the reentry process is an 
extremely difficult time that is filled with stressful events that contribute to both relapse and other 
excess morbidity and mortality. For example, reuniting with family, the need for housing and 
income, and the complexities of interacting with probation and parole are among the issues that 
offenders face after release.64,65 In addition, returning to an environment rich in drug cues could be 
related to a rapid return to drug use following long periods of incarceration, and also suggests the 
need for ongoing treatment after release.66 
Despite the evidence for benefits of drug treatment for offenders with addiction, a much less 
intense program called drug education is the most typical service provided to incarcerated 
addicts.26,60 There is also some participation in self-help (i.e., Alcoholics Anonymous and other 12-
step groups) with more than 20% of both federal and state inmates with addiction problems 
participating in these groups while incarcerated.60 By contrast, less than 20% of inmates with drug 
use disorders receive formal treatment.5,60 Taxman and colleagues, in a recent survey of U.S. 
programs and organizations, showed that most correctional agencies offered some type of drug 
abuse treatment services, but few offenders were actually able to participate.26 The median 
percentage of offenders who had access to effective treatment services at any given time was 
generally under 10%.26 In particular, medications, proven effective in addressing opioid and alcohol 
addiction, have very low availability in justice settings,4,54 despite the fact that one recent 
randomized trial for heroin-dependent inmates found that those who started methadone prior to 
release were significantly less likely to use heroin or cocaine, or to engage in criminal activity 12 
months post-release than those who received only counseling.56,67,68 While the potential exists for 
immediate adoption of methadone maintenance for incarcerated opioid addicts, few U.S. prison 
systems have been receptive to this approach.54,69 
Furthermore, continuity of treatment outside of prison (which is essential to recovery70) is 
frequently missing when addicts leave prison or jail and reenter the community.36 Such lack of 
continuity has an impact not just on the addiction outcomes, but may also increase the risk of 
mortality from drug overdose and other causes.63 
Combined Public Health/Public Safety Approaches 
Given the inherent weakness of the two separate public health and public safety approaches to 
reducing crime and improving health outcomes, a key model has been developed that combines 
elements of both health and justice approaches. This “Combined Public Health/Public Safety 
Approach” builds on over 20 years of research documenting the effectiveness of drug treatment for 
addicts in the criminal justice system70,71 by combining key elements of the health and justice 
systems. Such approaches include: drug court models that link drug treatment with judicial 
supervision,72 prison and jail-based treatment combined with supervision and treatment during 
reentry,73–75 and the use of medication-assisted treatment for addiction.54,56,67–69 Drug court models, 
for instance, appear to be cost-effective in that for each dollar spent on drug courts, approximately 
four dollars is saved in reduced costs of incarcerations and health care.76 In addition, therapeutic 
community and counseling approaches incorporated into justice settings have been shown to reduce 
drug use and recidivism.77 Individuals who participated in prison-based therapeutic communities 
with a community-based program post-incarceration were seven times more likely to be drug-free 
and three times less likely to be arrested for criminal behavior than those not receiving treatment 
after three years post-release.75,78 Key to the combined approaches is collaboration between drug 
abuse treatment and criminal justice system professionals and the use of monitoring, supervision, 
and potential for legal sanctions by the justice system to encourage addicts to engage in drug 
treatment and change their behaviors over an extended period of time. 
The typical justice approach includes intermittent monitoring of behavior, including drug use, by 
probation/parole personnel with unpredictable but sometimes quite severe punishments for 
infractions, including positive testing for drug use (e.g., long-term incarceration if successfully 
prosecuted). By contrast, a combined public health/public safety approach, especially those 
promulgated under drug court models, uses an intense form of justice supervision in which 
offenders with particular behavioral problems are seen frequently by court personnel in a process 
informed by psychological science: encouragement and positive reinforcement of behavior change 
and careful monitoring with predictable and immediate consequences for infractions.79 
The National Institute on Drug Abuse (NIDA) recently issued a publication entitled Principles of 
Drug Abuse Treatment for Criminal Justice Population, which synthesizes research on drug abuse 
treatment for criminal justice-involved drug abusers,45 advocating for the combined public 
health/public safety approaches to address addiction as well as related behavioral and medical 
conditions and recidivism. As outlined in Table 2.1, these principles form the basis of a combined 
public health/public safety approach to intervention with addicts in justice settings and depend on a 
coordinated response by criminal justice agencies, drug abuse treatment providers, mental health 
and physical health care organizations, and social service agencies. 
<Insert Compton Table 2.1 here> 
Effective integration of drug treatment and related medical interventions into criminal justice 
settings requires matching the intervention to the unique needs of different justice organizations 
(Table 2.2). For example, arrest is an entry point into the justice system and may alert an individual 
to the severity of their drug use. This phase can provide an opportunity for immediate evaluation of 
drug use and related health care needs. Since jail stays are usually brief, the interventions best suited 
to this environment may include screening for the various substance disorders (tobacco, drug, and 
alcohol abuse), other mental illnesses (i.e., co-occurring mental illnesses), and medical diseases 
(e.g., tuberculosis, STDs, HIV, and hepatitis B/C), the delivery of a brief intervention intended to 
boost motivation to seek treatment, and/or referral to community-based treatment providers. 
Similarly, each step in the criminal justice process (e.g., arrest, trial, sentencing, corrections, and 
reentry) lends itself to specific intervention opportunities, based on the specific key stakeholders 
who play a role in sanctioning and supervising offenders at that step in the justice process. 
<Insert Compton Table 2.2 here> 
A key element to implementing the principles of drug abuse treatment for criminal justice 
populations is for the two disparate health and justice systems to coordinate as they address an 
addict’s drug use, behavioral and health care needs, and criminal behavior. It is essential for the 
drug treatment staff to be aware of and tailor their approaches to the justice supervision 
requirements of their patients. In addition, drug abuse treatment outcomes are improved when 
antisocial and criminal behaviors are also targets of clinical attention.80 Justice system staff need to 
be aware of and tailor their approaches based on an understanding of addiction (including the use of 
positive reinforcement, warning signs for mental health decompensation and relapse, and need for 
more intense treatment) in order to maximize their impact on reducing crime and enhancing 
recovery. 
Next Steps 
A combined public health/public safety approach to addictions, mental illness, and related health 
conditions has the potential to impact a wide range of outcomes important to justice, behavioral 
health, and health care systems. This model provides a mechanism to maximize effectiveness in 
dealing with criminal activity and recidivism associated with drug use, which are of central 
importance to public safety officials. Likewise, mental illness, addiction, and infectious disease 
outcomes important to treatment providers are enhanced when combined approaches are applied. If 
this is true, why aren’t these approaches used universally? Organization and management 
constraints, including a lack of infrastructure to support information sharing, high caseloads for 
criminal justice supervisors, inadequately staffed and trained drug treatment programs, and separate 
funding streams, create significant impediments to the implementation of these approaches. A lack 
of effective brief interventions may also play a role, and one approach that appears promising, 
especially for arrest and jail phases which generally have short time periods for intervention, is the 
use of screening combined with brief intervention (or linkage to treatment, depending on an 
individual’s severity). This approach builds on established substance use Screening and Brief 
Intervention or Referral to Treatment (SBIRT) models in general medical settings.81 In addition, 
because of their efficiency, technology-assisted implementation may make SBIRT approaches 
especially easy to administer.82 
Next steps are twofold and include: First, applying principles of implementation science to build 
an evidence base on how to export effective principles of drug abuse treatment into criminal justice 
settings while simultaneously figuring out ways to create and sustain public health/public safety 
collaborations.83 Second, applying effective implementation frameworks for addictions and other 
related health conditions. These approaches could be applied to mental illness as well as general 
health conditions where behavior plays a key role in disease progression and/or transmission (e.g., 
HIV and other STDs, tuberculosis, and hepatitis).84 
Conclusions 
There are many barriers to treatment for drug-involved offenders, including lack of resources, 
infrastructure, and treatment staff. Addiction remains a stigmatized disease that is often not 
regarded by the criminal justice system as a medical condition and as a consequence is not afforded 
the same guarantee of treatment like other medical conditions. In addition, the criminal justice 
system lacks the staff and resources needed to identify and treat frequently co-occurring mental and 
physical health conditions. 
For behaviors that are fundamentally linked to drug addiction4,85 punishment alone is a 
temporary stopgap approach. The irony is that approaches that integrate strengths of both the public 
health and public safety systems can be more effective than stand-alone arrest and incarceration in 
improving public safety outcomes. Marked increases in the number of offenders with drug addiction 
and other serious comorbid conditions make it imperative that we continue to respond with smarter 
methods. We believe a combined public safety/public health approach holds the most promise for 
addressing the multiple drug abuse, mental health, and health care needs of the criminal justice 
system 
Success in the adoption, implementation, and sustainability of this promising new approach 
requires a culture shift in both the public health and safety systems simultaneously. The public 
safety system, designed to enforce laws and punish illegal drug use, must recognize the role they 
can play in improving not just crime rates but community health by facilitating participation in 
addiction, mental health, and medical treatment. Similarly, public health officials must reach into 
the public safety system to establish collaborative mechanisms to deliver care. Finally, 
policymakers need to recognize that an integrated approach is not intended to be “soft on crime.” It 
is often more rigorous in terms of close follow up of offenders and is designed specifically to 
reduce crime, in addition to addressing serious health needs. Overall, not treating the drug-abusing 
offender is a missed opportunity to simultaneously impact public health and public safety. 
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Table 2.1  NIDA Principles of Drug Abuse Treatment for Criminal Justice Populations75 
 
Treatment Principles 
1 Drug addiction is a chronic brain disease that affects behavior 
2 Recovery from drug addiction requires effective treatment, followed by continued care. 
3 Duration of treatment should be sufficiently long to produce stable behavioral changes 
4 Assessment is the first step in treatment 
5 
Tailoring services to fit the needs of the individual is an important part of effective drug 
abuse treatment for criminal justice populations 
6 Drug use during treatment should be carefully monitored 
7 Treatment should target factors that are associated with criminal behavior 
8 
Criminal justice supervision should incorporate treatment planning for drug abusing 
offenders, and treatment providers should be aware of correctional supervision 
requirements 
9 Continuity of care is essential for drug abusers re-entering the community 
10 
A balance of rewards and sanctions encourages prosocial behavior and treatment 
participation 
11 
Offenders with co-occurring drug abuse and mental health problems often require an 
integrated treatment approach 
12 Medications are an important part of treatment for many drug abusing offenders 
13 
Treatment planning for drug abusing offenders who are living in or re-entering the 
community should include strategies to prevent and treat serious, chronic medical 
conditions such as HIV/AIDS, hepatitis B and C, and tuberculosis 
 

LRH: Mental Health in Public Health         RRH: 2. Addressing Addiction and High Risk Behaviors  
Table 2.2  Intervention Opportunities in Criminal Justice Systems21 
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<TFN> a TASC is the national Treatment Accountability for Safer Communities organization. Its interventions are based on a case management model for integrating 
criminal justice and drug abuse treatment services. </TFN> 
